The shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has been pegged with a rating of Overweight by Cantor Fitzgerald in its latest research note that was published on September 21st, 2018. Cantor Fitzgerald wasn’t the only research firm that published a report of Catalyst Pharmaceuticals, Inc., with other equities research analysts also giving their opinion on the stock. Piper Jaffray advised investors in its research note published on September 7th, 2018, to Overweight the CPRX stock. The stock had earned Overweight rating from Piper Jaffray when it published its report on October 5th, 2016. The stock was given Neutral rating by Piper Jaffray in its report released on April 26th, 2016, the day when the price target on the stock was placed at $1. ROTH Capital was of a view that CPRX is Buy in its latest report on September 30th, 2014 while giving it a price target of $6. ROTH Capital thinks that CPRX is worth Buy rating. This was contained in the firm’s report on September 16th, 2014 in which the stock’s price target was also moved to $5.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 0 believe it has the potential for further growth, thus rating it as Hold while 1 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $9.33. The price of the stock the last time has raised by 186.49% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 74.73.
The shares of the company added by 6.00% during the trading session on Tuesday, reaching a low of $4.96 while ending the day at $5.30. During the trading session, a total of 2.01 million shares were traded which represents a -22% decline from the average session volume which is 1.65M shares. CPRX had ended its last session trading at 5.00. Catalyst Pharmaceuticals, Inc. currently has a market cap of $550.56M while its P/E earnings growth sits at 42.68, with a beta of 2.46. Catalyst Pharmaceuticals, Inc. debt-to-equity ratio currently stands at 0.00, while its quick ratio hovers at 5.10. CPRX 52-week low price stands at $1.85 while its 52-week high price is $6.16.
The Catalyst Pharmaceuticals, Inc. generated $28.84 million in revenue during the last quarter, which is slightly higher than the $18.49 million predicted by analysts. Catalyst Pharmaceuticals, Inc. has the potential to record -0.28 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Deutsche Bank published a research note on January 11th, 2019 where it informed investors and clients that Hanesbrands Inc. (NYSE:HBI) is now rated as Hold. Their price target on the stock stands at $16. Piper Jaffray also rated HBI as Resumed on September 7th, 2018, with its price target of $30 suggesting that HBI could surge by 19.06% from its current share price. Even though the stock has been trading at $14.54/share, analysts expect it to surge higher by 0.21% to reach $18.00/share. It started the day trading at $15.26 and traded between $14.35 and $14.57 throughout the trading session.
A look at its technical shows that HBI’s 50-day SMA is 16.30 while its 200-day SMA stands at 16.36. The stock has a high of $19.38 for the year while the low is $11.57. The company’s P/E ratio currently sits at 9.51, while the P/B ratio is 4.68. At the moment, only of Hanesbrands Inc. shares were sold short. The company’s average trading volume currently stands at 4.61M shares, which means that the short-interest ratio is just 7.30 days. Over the past seven days, the company moved, with its shift of -3.06%. Looking further, the stock has dropped -11.59% over the past 90 days while it lost -21.67% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Vanguard Group Inc bought more HBI shares, increasing its portfolio by +1.17% during the last quarter. This move now sees The Vanguard Group Inc purchasing 452,820 shares in the last quarter, thus it now holds 39,249,941 shares of HBI, with a total valuation of $631,531,551. SSgA Funds Management Inc meanwhile bought more HBI shares in the recently filed quarter, changing its stake to $315,436,180 worth of shares. BlackRock Fund Advisors followed the path by increasing its HBI portfolio by +0.23% in the quarter. This means that BlackRock Fund Advisors bought 41,478 shares in the last quarter and now controls 18,013,386 shares of the HBI stock, with the valuation hitting $289,835,381.
Similarly, Shapiro Capital Management LLC increased its Hanesbrands Inc. shares by +3.08% during the recently filed quarter. After buying 446,477 shares in the last quarter, the firm now controls 14,933,804 shares of Hanesbrands Inc. which are valued at $240,284,906. In the same vein, Diamond Hill Capital Management increased its Hanesbrands Inc. shares by during the most recent reported quarter. The firm bought 2,762,854 shares during the quarter which increased its stakes to 13,956,552 shares and is now valued at $224,560,922. Following these latest developments, around 0.50% of Hanesbrands Inc. stocks are owned by institutional investors and hedge funds.